Figure 5
From: Intracellular targets of RGDS peptide in melanoma cells
RGDS effect require survivin expression. SK-MEL-110 were transfected with human survivin siRNA or with control siRNA before RGDS treatment. SiGLO Lamin A/C siRNA was used as control of transfection efficiency. A Top: Survivin silencing was confirmed by western blotting after 72 h transfection. Bottom: FGF-2 (10 ng/ml)-induced proliferation in survivin-silenced or in control, after RGDS treatment for 48 h (* p < 0.05 vs FGF-2 and # p < 0.005 vs FGF-2 in silenced cells). Three independent experiments were performed in duplicate. B Top: Full length HA-tagged survivin was over-expressed in melanoma cells before RGDS treatment. Over-expression was confirmed by western blotting after 24 h transfection. Bottom: RGDS effect on FGF-2-induced proliferation in transfected-SK-MEL-110 after 48 h treatment (p < 0.01 vs FGF-2). Three independent experiments were performed in duplicate.